NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies (NCT07563829)
A Phase 1 Dose-Escalation Study of NPX372, a Bispecific Antibody Targeting B7-H7 and CD3, in Selected Solid Tumor Malignancies
🩺 Plain-English Summary (8th-Grade Level)
NPX372 is an antibody drug (protein drug) that blocks a specific protein which is found to be increased on the surface of cancer cells called B7-H7 and, at the same time, binds to immune cells (T cells) through a receptor called CD3. The effect of this binding is to activate T cells to kill cancer cells with B7-H7. In this research study we are: * Evaluating the safety and possible effectiveness of NPX372. * Identifying a safe and tolerable dose or doses for further study. Participants who are treated will receive an intravenous (IV) infusion of NPX372 if their disease has not progressed, and be closely monitored by the treating physicians.
Who can join: Review the eligibility criteria below.
Location: University of California - San Diego — La Jolla, California
Age range: 19 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- University of California - San Diego — La Jolla, California
- Johns Hopkins — Baltimore, Maryland
- Montefiore — The Bronx, New York
- Sarah Cannon Research Institute — Nashville, Tennessee
- MD Anderson Cancer Center — Houston, Texas
- NEXT — Fairfax, Virginia
📞 Contact the Study Coordinator
Phone: (508) 214-1115
Email: NPX372-001@nextpointtx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Malignant Neoplasm
- Cryoablation for the Treatment of Metastatic Cancer — Houston, Texas
- Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II) — Houston, Texas
- Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases — Houston, Texas
- A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 — Baltimore, Maryland
- Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer — Buffalo, New York
Explore by condition: All Metastatic Malignant Neoplasm clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.